Moderna Inc said on Wednesday that its COVID-19 vaccine booster, which targets both the original coronavirus strain and omicron, produced a better immune response to the variant than the original vaccine.
The booster increased virus neutralizing antibodies by a factor of eight in one study. The vaccine was generally well tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 microgram level.
“We are submitting our preliminary data and analysis to regulators in hopes that the omicron-containing bivalent booster will be available in late summer,” Chief Executive Stephane Bancel said in a statement.
Visit our dedicated page for more news about the coronavirus.
Moderna’s stock rose 2 percent in premarket trading.
Japan will open to tourists after two years, but only with masks, guides
COVID-19 cases in Saudi Arabia, UAE increasing as global number rises
UAE achieves 100% vaccination target for COVID-19